Author(s):
E Shri Ganesh Kumar, Rajesh Meshram, Reneesh Jaiswal
Email(s):
rjaiswalpharma123@gmail.com
DOI:
10.52711/0974-4150.2026.00054 
Address:
E Shri Ganesh Kumar1, Rajesh Meshram2, Reneesh Jaiswal3
1Student, Department of Pharmaceutical Chemistry, School of Pharmacy, Chouksey Engineering College, Bilaspur Chhattisgarh, India.
2Assistant Professor, Department of Pharmaceutical Chemistry, School of Pharmacy, Chouksey Engineering College, Bilaspur Chhattisgarh, India.
3Associate Professor, Department of Pharmaceutical Chemistry, School of Pharmacy, Chouksey Engineering College, Bilaspur Chhattisgarh, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 4,
Year - 2026
ABSTRACT:
Thyrotropin-releasing hormone or TRH, the hypothalamically secreted neuropeptide that can be taken orally, produces an extensive range of biological effects. For example, apart from being involved in the regulation of the pituitary-thyroid axis through stimulating the secretion of thyrotropin, TRH has been shown to modulate the activity of various neurobiological systems. Because of the therapeutic potential of TRH as a treatment for multiple CNS disorders, there is considerable interest in developing CNS-selective and metabolically stable derivatives of TRH. TRH exerts its biological effect through two G-protein-coupled TRH receptors (i.e., TRH-R1; TRH-R2). The specific distribution of these receptors provides a target for the development of subtype specific derivatives of TRH with enhanced CNS activity and no hormonal effect. This review provides a comprehensive analysis regarding the chemistry and biological characteristics of TRH and its derivatives. This review will also discuss the most recent discoveries regarding TRH-R2-selective derivatives, TRH super agonists, as well as TRH derivatives that have enhanced metabolic stability and recently developed targeted delivery systems for TRH derivatives.
Cite this article:
E Shri Ganesh Kumar, Rajesh Meshram, Reneesh Jaiswal. Structure Activity Relationship and Pharmacological Profile of TRH Hormone. Asian Journal of Research in Chemistry.2026; 19(4):357-2. doi: 10.52711/0974-4150.2026.00054
Cite(Electronic):
E Shri Ganesh Kumar, Rajesh Meshram, Reneesh Jaiswal. Structure Activity Relationship and Pharmacological Profile of TRH Hormone. Asian Journal of Research in Chemistry.2026; 19(4):357-2. doi: 10.52711/0974-4150.2026.00054 Available on: https://ajrconline.org/AbstractView.aspx?PID=2026-19-4-11
REFERENCES:
1. Vargas Y, et al. Thyrotropin-releasing hormone and food intake in mammals. Front Endocrinol. 2024; 15: 11205479.
2. Li X, et al. Emerging roles, mechanisms, and therapeutic potential of TRH. Brain Sci. 2026; 16(2): 229.
3. Zheng Y, et al. Functional evolution of thyrotropin-releasing hormone signaling systems. Front Endocrinol. 2025; 16:11890989.
4. Joseph-Bravo P, et al. TRH: the first hypophysiotropic hormone revisited. J Endocrinol. 2015; 226(2): T85–T92.
5. Rehman G, et al. Thyroid hormone receptor beta and endocrine regulation. Biomed Pharmacother. 2023; 162: 114678.
6. Kobayashi N, et al. Synthesis and evaluation of TRH mimetics with CNS activity. Bioorg Med Chem. 2021; 29: 115876.
7. Alvarez E, et al. new efforts to demonstrate TRH as a therapeutic agent. Int J Mol Sci. 2023; 24(13): 10456.
8. McMackin R, et al. JAK4D: a novel TRH analog for neurodegenerative disorders. Neuropharmacology. 2026; 210: 109034.
9. Kelly J, et al. TRH-based compounds and neurodegenerative models. Neuropharmacology. 2014; 89: 389–399.
10. Vale W. Pharmacology of thyrotropin-releasing factor. In: Handbook of Experimental Pharmacology. Springer; 2010. p. 45–67.
11. Charli JL, et al. TRH-degrading ectoenzyme as therapeutic target. Int J Mol Sci. 2020; 21(10): 3552.
12. Guillemin R, Schally AV. Structure and synthesis of TRH. Science. 1969; 165(3892): 175–177.
13. Gary KA, et al. TRH hypothesis of homeostatic regulation. J Pharmacol Exp Ther. 2003; 305(2): 410–416.
14. Yarbrough GG, et al. TRH in the neuroaxis: therapeutic implications. Med Hypotheses. 2007; 69(6): 1249–1256.
15. Parker CR, et al. TRH binding sites in human brain. Peptides. 1984; 5(4): 629–635.
16. Itadani H, et al. Cloning of TRH receptor subtype TRHR2. BiochemBiophys Res Commun. 1998; 250(1): 68–71.
17. Griffiths EC. Clinical applications of TRH. Clin Endocrinol. 1987; 26(2): 123–135.
18. Boschi G, et al. Antinociceptive properties of TRH. Eur J Pharmacol. 1983; 94(3–4): 317–322.
19. BenchChem. Chemistry of TRH and its analogs: a guide for drug development. 2020.